Trial results

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

NCT07537088 on ClinicalTrials.gov · last registry update 2026-04-22

An unusually large phase 4: 468 participants, more than double the 72 typical for the stage. Due to report April 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Urine Albumin-to-Creatinine Ratio（UACR）. Sponsors move these dates routinely; any movement since this site started watching is listed below. dulaglutide is approved in the US, but not for chronic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

dulaglutide

Trulicity

Sponsor

First Affiliated Hospital of Wannan Medical College

Sponsor type

Other

Enrollment

468

Started

2026-05

Primary completion

2027-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Urine Albumin-to-Creatinine Ratio（UACR）

Conditions studied

T2DM (Type 2 Diabetes Mellitus) · CKD - Chronic Kidney Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.